A b s t r a c t Introduction: Hospital length of stay (LoS) and hospital readmissions are metrics of healthcare performance. We examined the association between these two metrics in older patients hospitalized with decompensated heart failure (HF). Material and methods: Eight thousand and forty-nine patients hospitalized for HF in 106 U.S. hospitals had a median LoS of 5 days; among them, 3777 had a LoS > 5 days. Using propensity scores for LoS > 5 days, we assembled 2723 pairs of patients with LoS 1-5 vs. > 5 days. The matched cohort of 5446 patients was balanced on 40 baseline characteristics. We repeated the above process in 7045 patients after excluding those with LoS > 10 days, thus assembling a second matched cohort of 2399 pairs of patients with LoS 1-5 vs. 6-10 days. Hazard ratios (HR) and 95% confidence intervals (CI) for outcomes associated with longer LoS were estimated in matched cohorts. Results: In the primary matched cohort (n = 5446), LoS > 5 days was associated with a higher risk of all-cause readmission at 30 days (HR = 1.16; 95% CI: 1.04-1.31; p = 0.010), but not during longer follow-up. A longer LoS was also associated with a higher risk of mortality during 8.8 years of follow-up (HR = 1.13; 95% CI: 1.06-1.21; p < 0.001). LoS had no association with HF readmission. Similar associations were observed among the matched sensitivity cohort (n = 4798) that excluded patients with LoS > 10 days. Conclusions: In propensity score-matched balanced cohorts of patients with HF, a longer LoS was independently associated with poor outcomes, which persisted when LoS > 10 days were excluded.
Introduction
Heart failure (HF) is the leading cause for 30-day all-cause readmission among older patients in the United States [1] , the reduction of which is a focus of the Affordable Care Act, the 2010 comprehensive health care reform law [2] . Hospitals, on the other hand, are also en-couraged by the Medicare Inpatient Prospective Payment System to have a shorter length of stay (LoS) [3, 4] , which has been shown to be variously associated with outcomes [5] [6] [7] . In the current study, we examined the association between LoS and hospital readmission, two metrics of healthcare performance, in a propensity score-matched cohort of hospitalized patients with HF.
Material and methods

Data source and study population
Data for the study were collected from the Alabama Heart Failure Project, a registry of Medicare beneficiaries hospitalized for HF in the state of Alabama, the details of which have been previously published [8] [9] [10] . Briefly, extensive baseline data were collected on 8555 discharged patients from 106 Alabama hospitals during 1998-2001 with a principal discharge diagnosis of HF [11] [12] [13] . Medicare beneficiaries are the recipients of the United States government program called Medicare that provides health care coverage to American citizens 65 years or older, and to certain younger people with disability or permanent kidney failure requiring dialysis or a transplant [14] .
Study variables
Data on baseline characteristics including comorbidities, medications, laboratory, and in-hospital events were collected by chart abstraction. Our exposure variable was LoS, which was calcu-lated by subtracting the date of admission from the date of discharge. Of the 8049 patients discharged alive, 3777 had longer than median LoS of 5 days (25-75 percentile, 4-8 days; 5-95 percentile, 2-15 days; 1-99 percentile, 2-25 days; Figure 1) . Our outcome variables included all-cause readmission, HF readmission, all-cause mortality, and the combined endpoint of all-cause readmission or mortality. All outcomes were examined at 30 days, 12 months, and during the overall 8.8 (median = 2.5) years of follow-up. Information on outcome events and times to those events were obtained from the Medicare data files [8] .
Assembly of a balanced study cohort
We assembled a primary propensity scorematched cohort in which patients with a longer and a shorter LoS would be balanced on key measured baseline characteristics [15] [16] [17] . We estimated propensity scores for LoS > 5 days for each of the 8049 patients using a logistic regression model based on 40 baseline characteristics displayed in Figure 2 [17, 18] . We then used a greedy matching protocol to match 2723 patients with LoS > 5 days with another 2723 patients who had LoS of 1-5 days and similar propensity scores, thus assembling a matched cohort of 5446 patients ( Figure 1 ) [19, 20] .
Assembly of a balanced sensitivity cohort
To determine whether the results of the study could be replicated after excluding a potentially sicker cohort of patients with long LoS, we repeat- Pre-match cohort after excluding patients with length of stay > 10 days (n = 7045)
Estimate propensity scores for length of stay > 5 days and match 1 : 1 by propensity scores Sensitivity matched cohort (n = 4798) ed the above process in 7045 patients after excluding those with LoS > 10 days. Of these, 2773 had LoS 6-10 days ( Figure 1 ). The assembled second sensitivity matched cohort of 2399 pairs of patients with LoS 1-5 vs. 6-10 days was also balanced on 40 baseline characteristics.
Statistical analyses
Pearson c 2 and Wilcoxon rank-sum tests were used for descriptive analyses to compare between-group differences in baseline characteristics as appropriate. Kaplan-Meier survival plots for all-cause mortality by the two LoS categories during the overall follow-up of 8.8 (median = 2.5) years were generated using the primary matched data. Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for outcomes associated with longer LoS in both matched cohorts. We also examined the association of LoS with the primary outcome among the 8049 pre-match patients using Cox regression models, separately adjusting for propensity scores and the 40 variables used to estimate propensity scores. We then fitted restricted cubic spline models with 4 knots at 3, 5 (reference), 7 and 10 days to assess nonlinearity of the relationship of LoS with mortality during 8.8 (median = 2.5) years of follow-up.
To examine whether significant associations observed in our matched data could be explained away by an unmeasured baseline characteristic, we conducted formal sensitivity analyses using Rosenbaum's approach [21] . From the 2723 pairs of matched patients, we identified pairs in which we could directly compare survival times within the pair to determine whether one member of the pair clearly had a longer survival or event-free survival than the other member. We then used the sign-score test to calculate "sensitivity bounds" for a hypothetical unmeasured confounder to determine how much it would need to increase the odds of having a longer LoS to explain away any significant association between LoS and outcomes. A significant sign-score test provides strong evidence of a relationship between longer LoS and time to death. Our sensitivity analysis assumes that the potential unmeasured confounder is a binary baseline characteristic that is a near perfect predictor of the outcomes and also not strongly correlated with any of the 40 baseline characteristics used in our propensity score model. However, sensitivity analysis cannot determine whether such an unmeasured confounder exists. All statistical tests were two-tailed with a p-value < 0.05 considered significant. IBM SPSS Statistics for Windows, Version 25 (IBM Corp. Armonk, NY) and SAS version 9.4 (SAS Institute Inc., Cary, NC) were used for data analyses.
Results
Baseline characteristics
Patients in our propensity score-matched cohort (n = 5446) had a mean age of 75.8 ±10.8 years, 58% were female, and 25% were African American. Prior to matching, HF patients with LoS > 5 days were older and had a higher prevalence of comorbidities and in-hospital events (Table I) . Post-match absolute standardized differences were < 10% for all 40 measured baseline characteristics, suggesting no residual consequential imbalance between the two LoS groups (Figure 2 ). After matching, patients in the sensitivity cohort were also balanced on all 40 measured baseline characteristics.
Length of stay and readmission in the matched primary cohort
30-day all-cause readmission occurred in 20% and 23% of matched patients with LoS 1-5 and > 5 days, respectively (hazard ratio (HR) = 1.16; 95% confidence interval (CI): 1.04-1.31; p = 0.010; Table II ). Findings from our sensitivity analyses demonstrate that the significant associations of LoS > 5 days and 30-day all-cause readmission were insensitive to unmeasured confounders. Of the 2723 matched pairs, in 965 pairs we were able to determine which patient within a matched pair had a shorter 30-day total readmission-free survival, and in 55% (528/965) of those pairs, they belonged to the longer LoS group (sign-score test p = 0.003). A hidden baseline characteristic would need to increase the odds of having a longer LoS by 6%. HR (95% CI) for 30-day all-cause readmission associated with LoS as a continuous variable in the matched data was 1.02 (1.01-1.04; p < 0.001).
In the pre-match cohort, multivariable-adjusted and propensity score-adjusted HRs (95% CIs) for 30-day all-cause readmission associated with LoS > 5 days were both 1.19 (1.07-1.32; p = 0.001). LoS had no association with 30-day HF readmission. Associations of a longer LoS and all-cause readmission at 12 months and during 8.8 (median = 2.5) years of follow-up are displayed in Table II. 30-day HF readmission occurred in 7% and 8% of matched patients with LoS 1-5 and > 5 days, respectively (HR = 1.12; 95% CI: 0.92-1.35; p = 0.266; Table II ). There was no association with HF readmission during longer follow-up.
Length of stay and all-cause mortality in the matched primary cohort 30-day all-cause mortality occurred in 5% and 7% of matched patients with LoS 1-5 and > 5 days, respectively (HR = 1.41; 95% CI: 1.12-1.76; A hidden baseline characteristic would need to increase the odds of having a longer LoS by 6%. Findings from our restricted cubic spline analysis demonstrated that LoS > 10 days is associated with a significantly higher risk for overall all-cause mortality and that there is no evidence that this association is nonlinear (p for test of non-linearity, > 0.20 and 0.07 in the matched and pre-match data, respectively (Figure 4 ). In the pre-match cohort, multivariable-adjusted and propensity score-adjusted HRs (95% CIs) for 30-day all-cause mortality associated with LoS > 5 days were 1.44 (1.17-1.77; p = 0.001) and 1.40 (1.14-1.72; p = 0.001), respectively.
Findings from the matched sensitivity cohort
30-day all-cause readmission occurred in 20% and 22% of matched patients with LoS 1-5 and 6-10 days, respectively (HR = 1.15; 95% CI: 1.02-1.30; p = 0.026; Table III ). 30-day all-cause mortality occurred in 5% and 6% of matched patients with LoS 1-5 and 6-10 days, respectively (HR = 1.32; 95% CI: 1.03-1.68; p = 0.027; Table III ). The associations of LoS with other outcomes in the matched sensitivity cohort are displayed in Table III .
Discussion
Findings from our study demonstrate that in older patients hospitalized for HF, a LoS > 5 days was associated with a higher risk of 30-day allcause readmission and all-cause mortality, but not with HF readmission. Further, only the association with all-cause mortality persisted during longer follow-up. We also observed that these findings persisted when we excluded patients with LoS > 10 days. These findings from rigorously assem-bled, propensity score-matched cohorts highlight the complex interplay between LoS and outcomes in older patients with HF.
A potential explanation for these associations include confounding by conditions and complications that may have necessitated the longer LoS [22, 23] . However, the findings of our study may not be explained by the subset of very sick patients with unusually long LoS, as we found similar results when we repeated our analysis after excluding those with LoS > 10 days. An examination of the baseline characteristics in the pre-match cohort demonstrated that patients in the longer LoS group had a lower mean blood pressure, and a higher prevalence of pre-admission comorbidities, admission pulmonary edema, and in-hospital complications, which have been shown to be associated with poor outcomes [24, 25] . These patients also had a lower prevalence of pre-admission use of ACE inhibitors and b-blockers, drugs known to improve outcomes [26, 27] . Although the distribution of these and other baseline characteristics was balanced after propensity score-matching, imbalanced unmeasured characteristics such as disease severity may act as confounders. For example, although the prevalence of pneumonia was similar after matching, it is possible that pneumonia in the longer LoS group was more severe or complicated. A longer LoS may also lead to Length of stay > 5 days Length of stay 1-5 days 12-month HR (95% CI) = 1.16 (1.06-1.27), p = 0.002 a higher prevalence of unmeasured confounders such as loss of function, strength, coordination, and mobility [28, 29] .
Several prior studies have examined the association of LoS with outcomes in patients hos-pitalized for HF [5] [6] [7] . Among 19,927 hospitalized patients with HF (2008-2011), compared with LoS 3-4 days, LoS 5-10 days was associated with a 17% higher risk of 30-day all-cause readmission and a 52% higher risk of 30-day all-cause mortal- ity, but had no association with HF readmission [6] . The mean age of the patients in that study and their 30-day outcome rates are similar to those in our study [6] . However, our study is distinguished by the use of propensity score matching, which allowed us to achieve and display balance in key measured baseline characteristics between the two LoS groups. Taken together, these findings suggest that a longer LoS has a stronger association with mortality than with readmission. Future studies need to examine underlying reasons why a longer LoS may increase the risk of death, but not of readmission, and develop and test interventions that may improve post-discharge survival among the high-risk subset of patients with longer LoS.
Our study has several limitations. As in any observational study, bias due to an unmeasured confounder is possible. Although the management of heart failure with reduced ejection fraction has evolved, the findings of the current study are similar to those observed in a more contemporary population of HF patients [6] . Additionally, we had no data on brain natriuretic peptides, the use of vasodilators, sacubitril/valsartan, or inotropic drugs, and drug-drug interactions [30] [31] [32] [33] [34] .
In conclusion, in older adults hospitalized for HF, when compared with a hospital length of stay of 1-5 days, a length of stay of 5-10 days is associated with a higher risk of both mortality and short-term readmission, but not with HF readmission.
